Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

The Effect of Light Therapy on Cellular Energy and Oxidative Stress in Healthy Adults and Type 1 Diabetic Patients (PBM-T1D)

12 oktober 2026 uppdaterad av: Joudi Shaker, University of Thi-Qar

Biochemical Study of Metabolic Regulation and Extraction of Mitochondrial Biomarkers in Type 1 Diabetes Mellitus in Thi-Qar Governorate, Iraq

The goal of this clinical trial is to evaluate the effects of low-level light therapy on cellular energy and oxidative stress in healthy adults and patients with Type 1 diabetes. The main questions it aims to answer are:

Does light therapy change adenosine triphosphate (ATP) levels and cytochrome c oxidase activity in blood cells? How does the intervention affect oxidative stress markers, specifically glutathione and malondialdehyde concentrations? Researchers will compare blood samples collected before the light therapy to those collected afterward to see if the intervention alters mitochondrial function. Researchers will also compare the responses of healthy volunteers to those of diabetic patients.

Participants will:

Provide a baseline blood sample. Receive red and near-infrared light exposure (660 nm and 850 nm) on their arms for 10 to 20 minutes using a therapy pad.

Provide a final blood sample immediately after the light exposure.

Studieöversikt

Status

Har inte rekryterat ännu

Detaljerad beskrivning

This study evaluates the metabolic effects of photobiomodulation on peripheral blood mononuclear cells in patients with Type 1 diabetes and healthy volunteers. The intervention applies red (660 nm) and near-infrared (850 nm) light to stimulate cytochrome c oxidase within the mitochondrial electron transport chain. This photon absorption increases cellular respiration and alters oxidative stress markers.

Researchers collect baseline venous blood samples from all participants to establish initial biochemical parameters. The clinical team isolates peripheral blood mononuclear cells using density gradient centrifugation. Following baseline collection, participants receive a single 10-to-20-minute light therapy session on the upper arm using a flexible light pad. Researchers collect a second venous blood sample immediately after the light exposure.

The laboratory analysis quantifies specific mitochondrial and metabolic variables in the cell lysates before and after the intervention. The primary metrics are adenosine triphosphate (ATP) concentration and cytochrome c oxidase specific activity. Secondary measures include malondialdehyde and glutathione to assess lipid peroxidation and antioxidant capacity. The research team also measures lactate and pyruvate levels to evaluate shifts in cellular glycolysis, alongside standard fasting plasma glucose monitoring. The comparative analysis evaluates differences in metabolic response between the diabetic cohort and the healthy matched controls.

Studietyp

Interventionell

Inskrivning (Beräknad)

30

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • TQ
      • Nasiriyah, TQ, Irak, 64001
        • Al Nasiriya Teaching Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

12 år till 40 år (Barn, Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 12 to 40 years.
  • Confirmed diagnosis of Type 1 Diabetes Mellitus based on American Diabetes Association criteria (patient group).
  • Insulin dependence (patient group).
  • Low serum C-peptide levels (patient group).
  • Fasting plasma glucose concentration <100 mg/dL (healthy control group).
  • Glycated haemoglobin (HbA1c) <5.7% (healthy control group).
  • Diabetes duration of at least 1 year (patient group).

Exclusion Criteria:

  • Diabetic ketoacidosis within the preceding month.
  • High-sensitivity C-reactive protein (hs-CRP) >10 mg/L or active infection.
  • Renal insufficiency.
  • Liver disease.
  • Pregnancy.
  • Smoking.
  • Use of antioxidant supplements, vitamin C, or vitamin E within the preceding month.
  • Autoimmune diseases other than Type 1 Diabetes Mellitus.
  • Haematological disorders.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Photobiomodulation Intervention

Researchers apply the photobiomodulation device to the arm of every enrolled participant, encompassing both the healthy volunteers and the patients diagnosed with Type 1 diabetes, for a strictly timed session lasting between 10 and 20 minutes.

Participants receive a single photobiomodulation session using a flexible light therapy pad. The device delivers red light at 660 nm and near-infrared light at 850 nm with an operating voltage of 5V and a working current of 1.7A. The pad is placed in direct contact with the upper arm of each participant for a timed duration of 10 to 20 minutes. Researchers evaluate cellular responses before and immediately after this single application.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Adenosine Triphosphate (ATP) Concentration
Tidsram: Baseline and immediately after the 10-to-20-minute light therapy session

Researchers measure ATP levels in blood cells using a specific assay kit to evaluate cellular energy production.

Baseline and immediately after the 10-to-20-minute light therapy session
Change in Cytochrome c Oxidase Activity
Tidsram: Baseline and immediately after the 10-to-20-minute light therapy session

Researchers assess the specific activity of cytochrome c oxidase in blood samples via a biochemical assay to determine mitochondrial function.

Baseline and immediately after the 10-to-20-minute light therapy session

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Malondialdehyde (MDA) Levels
Tidsram: Baseline and immediately after the 10-to-20-minute light therapy session

Researchers quantify MDA concentration in the collected blood samples to assess oxidative stress.

Baseline and immediately after the 10-to-20-minute light therapy session
Change in Lactate and Pyruvate Concentrations
Tidsram: Baseline and immediately after the 10 to 20-minute light therapy session

Researchers determine the concentrations of lactate and pyruvate in blood cells to analyze metabolic shifts.

Baseline and immediately after the 10 to 20-minute light therapy session
Change in Glutathione (GSH) Levels
Tidsram: Baseline and immediately after the 10-to-20-minute light therapy session

Researchers measure glutathione concentration in the blood samples to evaluate antioxidant capacity.

Baseline and immediately after the 10-to-20-minute light therapy session
Change in Blood Glucose Levels
Tidsram: Baseline and immediately after the 10-to-20-minute light therapy session

Researchers measure blood glucose concentrations in the collected blood samples to evaluate glycemic changes following the light therapy session.

Baseline and immediately after the 10-to-20-minute light therapy session

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Hattf B. Farhood, PhD, University of Thi-Qar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

13 oktober 2026

Primärt slutförande (Beräknad)

15 januari 2027

Avslutad studie (Beräknad)

15 januari 2027

Studieregistreringsdatum

Först inskickad

16 september 2026

Först inskickad som uppfyllde QC-kriterierna

16 september 2026

Första postat (Faktisk)

22 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 oktober 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

All individual participant data (IPD) that underlie the results reported in the published article will be shared after complete de-identification. This includes demographic characteristics and all measured biochemical variables (ATP concentration, cytochrome c oxidase activity, malondialdehyde, glutathione, lactate, pyruvate, and blood glucose) collected at baseline and immediately following the light therapy session.

Tidsram för IPD-delning

Data will become available immediately following the publication of the study results and will remain accessible for 5 years.

Kriterier för IPD Sharing Access

Data and supporting documents will be available to academic researchers who submit a methodologically sound proposal. Requesters must outline the specific aims of their intended analysis, such as meta-analyses or secondary evaluations related to photobiomodulation and cellular metabolism. Requests should be sent directly to the corresponding author via email. The principal investigator and the academic supervisory committee at Thi-Qar University will review all requests. This process prevents data misuse. Upon approval, the research team will transmit the de-identified datasets securely to the requester.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ANALYTIC_CODE

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera